Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707017 | 1.00 | CCR3 (0.32) | CCR3KCNH2MCHR1TSHRSMN1; SMN2 | |
| SCHEMBL20995986 | 1.00 | CCR3 (0.32) | CCR3KCNH2MCHR1TSHRSMN1; SMN2 | |
| SCHEMBL20995992 | 0.91 | SLC2A1 (0.35) | KCNH2GRIN2BJAK2JAK3 | |
| SCHEMBL19706892 | 0.91 | SLC2A1 (0.35) | KCNH2GRIN2BJAK2JAK3 | |
| SCHEMBL19706897 | 0.91 | SLC2A1 (0.34) | KCNH2TSHRSMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL20995977 | 0.91 | SLC2A1 (0.34) | KCNH2TSHRSMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL19706895 | 0.91 | SLC2A1 (0.34) | KCNH2TSHRSMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL19708645 | 0.90 | KCNH2 (0.35) | KCNH2GRIN2BJAK2JAK3 | |
| SCHEMBL19706841 | 0.90 | KCNH2 (0.35) | KCNH2GRIN2BJAK2JAK3 | |
| SCHEMBL20996016 | 0.86 | CCR3 (0.33) | CCR3KCNH2MCHR1BRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-05-30 | — | — | US | disclosed |
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-05-30 | — | — | US | disclosed |
| WO-2017211760-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211759-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, LAS1L, MRPL19 | CCR3 2671/4885KCNH2 2657/4885MCHR1 1845/4885 |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | CCR3 3545/4885KCNH2 3913/4885MCHR1 4570/4885 |
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | CCR3 2934/4885KCNH2 2772/4885MCHR1 1637/4885 |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | CCR3 3545/4885KCNH2 3913/4885MCHR1 4570/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | CCR3 3672/4885KCNH2 3933/4885MCHR1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.